Literature DB >> 35949294

A Hybrid Machine Learning Model Based on Semantic Information Can Optimize Treatment Decision for Naïve Single 3-5-cm HCC Patients.

Wenzhen Ding1, Zhen Wang1, Fang-Yi Liu1, Zhi-Gang Cheng1, Xiaoling Yu1, Zhiyu Han1, Hui Zhong1, Jie Yu1, Ping Liang1.   

Abstract

Background: Tumor recurrence is an abomination for hepatocellular carcinoma (HCC) patients receiving local treatment. Purpose: The aim of the study was to build a hybrid machine learning model to recommend optimized first treatment (laparoscopic hepatectomy [LH] or microwave ablation [MWA]) for naïve single 3-5-cm HCC patients based on early recurrence (ER, ≤2 years) probability.
Methods: This retrospective study collected 20 semantic variables of 582 patients (LH: 300, MWA: 282) from 13 hospitals with at least 24 months follow-up. Both groups were divided into training, validation, and test set, respectively. Five algorithms (logistics regression, random forest, neural network, stochastic gradient boosting, and eXtreme Gradient Boosting [XGB]) were used for model building. A model with highest area under the receiver operating characteristic curve (AUC) in a validation set of LH and MWA was selected to connect as a hybrid model which made decision based on ER probability. Model testing was performed in a comprehensive set comprising LH and MWA test sets.
Results: Four variables in each group were selected to build LH and MWA models, respectively. LH-XGB model (AUC = 0.744) and MWA-stochastic gradient method (AUC = 0.750) model were selected for model building. In the comprehensive set, a treatment confusion matrix was established based on recommended and actual treatment. The predicted ER probabilities were comparable with the actual ER rates for various types of patients in matrix (p > 0.05). ER rate of patients whose actual treatment consistent with recommendation was lower than that of inconsistent patients (LH: 21.2% vs. 46.2%, p = 0.042; MWA: 26.3% vs. 54.1%, p = 0.048). By recommending optimal treatment, the hybrid model can significantly reduce ER probability from 38.2% to 25.6% for overall patients (p < 0.001). Conclusions: The hybrid model can accurately predict ER probability of different treatments and thereby provide reliable evidence to make optimal treatment decision for patients with single 3-5-cm HCC.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Hepatocellular carcinoma; Laparoscopic hepatectomy; Microwave ablation; Treatment decision

Year:  2022        PMID: 35949294      PMCID: PMC9218628          DOI: 10.1159/000522123

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   12.430


  32 in total

1.  Radiomics Analysis Based on Multiparametric MRI for Predicting Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy.

Authors:  Ying Zhao; Jingjun Wu; Qinhe Zhang; Zhengyu Hua; Wenjing Qi; Nan Wang; Tao Lin; Liuji Sheng; Dahua Cui; Jinghong Liu; Qingwei Song; Xin Li; Tingfan Wu; Yan Guo; Jingjing Cui; Ailian Liu
Journal:  J Magn Reson Imaging       Date:  2020-11-20       Impact factor: 4.813

2.  Radiomics-based nomogram using CT imaging for noninvasive preoperative prediction of early recurrence in patients with hepatocellular carcinoma.

Authors:  Hong-Bo Zhu; Ze-Yu Zheng; Heng Zhao; Jing Zhang; Hong Zhu; Yue-Hua Li; Zhong-Yi Dong; Lu-Shan Xiao; Jun-Jie Kuang; Xiao-Li Zhang; Li Liu
Journal:  Diagn Interv Radiol       Date:  2020-06-03       Impact factor: 2.630

3.  Evolution of Laparoscopic Liver Surgery from Innovation to Implementation to Mastery: Perioperative and Oncologic Outcomes of 2,238 Patients from 4 European Specialized Centers.

Authors:  Giammauro Berardi; Stijn Van Cleven; Åsmund Avdem Fretland; Leonid Barkhatov; Mark Halls; Federica Cipriani; Luca Aldrighetti; Mohammed Abu Hilal; Bjørn Edwin; Roberto I Troisi
Journal:  J Am Coll Surg       Date:  2017-08-31       Impact factor: 6.113

4.  Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.

Authors:  Naïk Vietti Violi; Rafael Duran; Boris Guiu; Jean-Pierre Cercueil; Christophe Aubé; Antonia Digklia; Isabelle Pache; Pierre Deltenre; Jean-François Knebel; Alban Denys
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-03-02

5.  Feasibility of Extracted-Overlay Fusion Imaging for Intraoperative Treatment Evaluation of Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Yuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Takayuki Iwamoto; Junya Okabe; Manabu Takamura; Norihiko Fujita; Masatoshi Hori; Tetsuo Takehara; Masatoshi Kudo; Takamichi Murakami
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

6.  Efficacy of endoscopic ultrasound with artificial intelligence for the diagnosis of gastrointestinal stromal tumors.

Authors:  Yosuke Minoda; Eikichi Ihara; Keishi Komori; Haruei Ogino; Yoshihiro Otsuka; Takatoshi Chinen; Yasuo Tsuda; Koji Ando; Hidetaka Yamamoto; Yoshihiro Ogawa
Journal:  J Gastroenterol       Date:  2020-09-11       Impact factor: 7.527

7.  An evaluation of avatrombopag for the treatment of thrombocytopenia.

Authors:  Zain Mohammad Virk; David J Kuter; Hanny Al-Samkari
Journal:  Expert Opin Pharmacother       Date:  2020-11-11       Impact factor: 3.889

8.  Beneficial body mass index to enhance survival outcomes in patients with early-stage hepatocellular carcinoma following microwave ablation treatment.

Authors:  Jian-Ping Dou; Zhi-Yu Han; Fangyi Liu; Zhigang Cheng; Xiaoling Yu; Jie Yu; Ping Liang
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

Review 9.  Thermal ablation for hepatocellular carcinoma: what's new in 2019.

Authors:  Feipeng Zhu; Hyunchul Rhim
Journal:  Chin Clin Oncol       Date:  2019-12

10.  Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.

Authors:  Hanny Al-Samkari; Srikanth Nagalla
Journal:  Platelets       Date:  2021-02-14       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.